Specialty Enzymes Market is Projected to Record Significant Growth by 2025

The Specialty Enzymes Market is estimated to be valued at USD 4.4 billion in 2019 and is projected to reach USD 6.6 billion by 2025, recording a CAGR of 6.9% in terms of value. The growing concerns about the enzyme quality in pharmaceuticals & diagnostics and rise in demand for non-harmful biological catalysts are factors that are projected to drive the growth of the specialty enzymes market, globally.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21682828

Based on source, the specialty enzymes market is segmented into microorganism, plant, and animal. The microorganism segment is projected to witness the highest growth during the forecast period, as enzymes obtained from microbial sources lead to low production costs. Furthermore, they contain more predictable and controllable enzyme content. In addition, as enzymes obtained from microbial sources can be cultured in large quantities in a short period, microorganisms are the primary source of specialty enzymes.

By type, the specialty enzymes market is segmented into carbohydrases, proteases, lipases, polymerases & nucleases, and other enzymes (such as catalases, laccases, oxidases, phosphatases, kinases, esterases, and pectinases). Polymerases & nucleases have been bolstering the biotechnological advancements for research & developments in the various industries. They have been used for molecular cloning to manipulate nucleic acids to generate advanced enzymes available today for commercial uses.

The specialty enzymes market in North America is dominating due to the increasing demand for enzymes in specialty applications. Technological innovations in machinery, optimization of production, logistics, and globalization of business have made the pharmaceutical industry one of the essential sectors in the North America region.

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=21682828

Leading companies are BASF (Germany), Novozymes (Denmark), Roche Holding (Switzerland), DuPont (US), Codexis (US), Dyadic International (US), Advanced Enzymes (India), Amano Enzymes (Japan), Sanofi (France), Biocatalysts (UK), Enzyme Supplies (UK), BBI Solutions (UK), Specialty Enzymes & Probiotics (US), Amicogen (South Korea), Antozyme Biotech (India), Enzyme Development Corporation (US), Nagase & Co. Ltd. (Japan), Sekisui Diagnostics (US), Merck (Germany), and Biovet (Bulgaria).

Target Audience:

• Enzyme manufacturing companies and government organizations
• Service providing company officials
• Government and research organizations
• Research officers
• CEOs and vice presidents
• Marketing directors
• Product innovation directors and related key executives from manufacturing companies and organizations operating in the market
• Manufacturing and marketing companies

Recent Developments

• DuPont Nutrition & Biosciences launched its industry-leading OPTIMASE portfolio. This portfolio contains bio-based enzymes, which will be used for the cleaning of medical instruments. The product range is aimed at high performance and reduction in enzyme stabilizing ingredients, while also saving space and cost.
• Roche Holding (Switzerland) entered into an agreement with Codexis (US) for providing enzymes. Codexis will supply EvoT4 DNA ligase to Roche. EvoT4 DNA ligase is a high-performance molecular diagnostic enzyme.
• BASF (Germany) entered into a cooperation agreement with Conagen (US), a leader in biotechnology research. Conagen has strong R&D capabilities for fermented ingredients. This decision will enable BASF to serve the market with one of the aroma ingredients with the highest demand—natural vanillin.
• Novozymes (Denmark) expanded its presence in East Africa. This allowed the company to meet consumer needs for enzyme products in the region.
• Sanofi (France) opened its first digitally enabled manufacturing facility in Framingham, Massachusetts. The new manufacturing facility has the technology of connecting the production process to R&D. This will improve the commercialization of new medicines.

Marker Research Report Insights & Consulting.